COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

Schizophrenia Research

Volumn 95, Issue 1-3, 2007, Pages 253-255

  Bertolino, Alessandro ^a,b,c   Caforio, Grazia ^a   Blasi, Giuseppe ^a,b   Rampino, Antonio ^a   Sinibaldi, Lorenzo ^c,d   Douzgou, Sophia ^c,d   Nardini, Marcello ^a   Weinberger, Daniel R ^b   Dallapiccola, Bruno ^c,d  

^a Section on Mental Disorders   (Italy)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; OLANZAPINE; VALINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ALLELE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CATECHOL O-METHYLTRANSFERASE; GENOTYPE; HUMANS; METHIONINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; VALINE;

EID: 34548160606     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.06.014     Document Type: Letter

References (6)

1. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., and Nardini M. Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia. Am. J. Psychiatry 161 10 (2004) 1798-1805
2. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 Suppl 1 (2006) S10-S14
3. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., and Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22 6 (2000) 642-649
4. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 3 (1996) 243-250
5. Molero P., Ortuno F., Zalacain M., and Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. (2007) (Mar 13, Electronic publication ahead of print)
6. Stefanis N.C., Van Os J., Avramopoulos D., Smyrnis N., Evdokimidis I., Hantoumi I., and Stefanis C.N. Variation in catechol-O-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry 56 7 (2004) 510-515